Changes to instructions on the administration of EpiPen® and EpiPen® Junior adrenaline autoinjector
Mylan UK has recently received an approval for a variation to the administration of EpiPen® and EpiPen® Junior adrenaline autoinjector. This update is in line with changes in the USA, Australia and some European countries. The changes have been implemented based on post marketing surveillance as well as the results of a review of relevant literature.
There is no change to the device or the drug (adrenaline); the change is in the instructions for use as outlined below:
- Reduced injection time from 10 to 3 seconds – this is based on research confirming delivery of adrenaline for 3 seconds is sufficient.
- Removal of the massage step after the injection – this step has been removed to simplify the process of administering EpiPen® or EpiPen® Junior.
The changes above are aimed to improve patient compliance.
ALK the pharmaceutical company that produces Jext® and Bausch and Lomb who produce Emerade® have, at present, no plans the change the method of administration of their adrenaline autoinjectors.